New formulation of its widely-used U. S. market-leading PSMA PET imaging agentcombines the diagnostic performance of PYLARIFY (piflufolastat F 18) with the potential for larger batches and greater patient availability PYLARIFY TruVu™ is expected to launch in 4Q 2026, with a phased geographic rollout to support a seamless customer transition BEDFORD, Mass.